# Ab&B Bio-Tech Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ab-b-bio-tech-co

- Industry: Biotechnology
- Headquarters: Taizhou, China
- Website: www.abbbio.com
- Latest round: Series A (Jan 8, 2019)
- Investors on record: 1

## About

Based in Taizhou, China, and established in 2015, Ab&B Bio-Tech Co., Ltd. is a biotechnology company that engages in the R&D, production, and sales of vaccines. The company's first phase plants, invested in CNY 500 million, cover 70 mu, and the building area is 50,000 square meters, which received the vaccine production license and laboratory animal use license. And its second phase plants, invested in CNY 500 million, cover 80mu, used for products industrial production. Moreover, it has more than 300 employees. And the company received 5 items of nationally registered trademarks and 17 items of invention patents. In August 2025, Ab&B Bio-Tech Co., Ltd. raised HKD 431.40 million in an IPO, selling 33.44 million shares at HKD 12.90 per share at the Hong Kong Exchanges and Clearing Limited, under the ticker 2627. Ab&B Bio-Tech Co., Ltd. provides vaccines, including childhood quadrivalent influenza virus subunit vaccines, adult quadrivalent influenza virus subunit vaccines, 23-valent pneumococcal polysaccharide vaccines and lyophilized human rabies vaccines. The adult quadrivalent influenza virus subunit vaccines have completed three-phase clinical trials, and NDA registration, which suits vaccination for children, and the elderly.

## Funding rounds

- Series A, Jan 8, 2019 — GTJA Investment Group

## Investors

- GTJA Investment Group (https://capitalatlas.ai/funds/gtja-investment-group) — Series A